Royalty Report: Drugs, Pain, Pharmaceuticals – Collection: 26587

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 11

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 11

Primary Industries

  • Drugs
  • Pain
  • Pharmaceuticals
  • Disease
  • Therapeutic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 26587

License Grant
We have licensed exclusive, worldwide, development and commercialization rights under an Agreement.

Remoxy is formulated with our Oradur technology and incorporates several abuse-deterrent properties with the convenience of twice-a-day dosing. Oxycodone is also the active drug ingredient in OxyContin®, a brand name narcotic painkiller.  Remoxy is intended for patients with chronic pain. Remoxy is currently in Phase III trials.

Field of Use
The rights granted apply to the pain management industry.

IPSCIO Record ID: 3602

License Grant
Subject to the terms and conditions of this Agreement and further subject to the pre-existing non-exclusive license granted by the Licensor, the Licensor hereby grants to Licensee the following licenses under Licensor's Technology and Patent Rights and under Licensor's ownership interest in Joint Technology and Joint Patent Rights, which licenses shall be exercisable only as set forth in this Agreement or in the Collaboration Agreement and for the conduct of the activities required or permitted in the performance of Licensee's obligations and exercise of its rights thereunder.  Parties entered into a collaborative agreement to develop and commercialize the Licensee’s drug candidate Remoxy and other abuse-resistant opioid painkillers.
License Property
Remoxy, which is an abuse-resistant version of long-acting oxycodone, is an investigational drug in late-stage clinical development for the treatment of severe to chronic pain.  Licensor has worldwide exclusive rights to commercialize Remoxy and the other abuse-resistant opioid drugs that are developed pursuant to the collaboration, other than in Australia and New Zealand.

IPSCIO Record ID: 8453

License Grant
The Licensee is the exclusive, worldwide commercial partner, with the Licensor, for Remoxy (except as to Australia/New Zealand).
License Property
The Licensor's lead drug candidate is called Remoxy (oxycodone) Extended-Release Capsules CII.

Remoxy is an investigational drug with a unique, controlled release formulation of oxycodone for patients with moderate-to-severe chronic pain and is designed to discourage common methods of tampering associated with prescription drug misuse and abuse.

The Licensor is a biopharmaceutical company that develops novel drugs.

Field of Use
The rights grants apply to the medical industry.

IPSCIO Record ID: 6705

License Grant
In a modification to its strategic alliance for REMOXY® the Licensee and the Licensor have amended the terms on sales outside the United States. The Licensee has also gained certain undisclosed rights related to the development of other opioid products covered by the collaboration Agreement.
License Property
REMOXY® is a strong painkiller with a unique formulation designed to reduce potential risks of unintended use.

IPSCIO Record ID: 3265

License Grant
The Licensor will grant the Licensee a non-exclusive, royalty-bearing future license to the Licensor Patent and other current and future Orange Book listable patents to market, manufacture and sell a generic version of Oxecta® in the United States.

The Licensee's license becomes effective January 1, 2022, approximately 23 months prior to the expected expiration of the Licensor Patent.

License Property
OXECTA is an immediate-release oral formulation of oxycodone HCl indicated for the management of acute and chronic moderate to severe pain where the use of an opioid analgesic is appropriate.

In June 2011, the U.S. Food and Drug Administration approved Oxecta® (oxycodone HC1 tablets) which incorporates the Aversion® technology. Oxecta® is an abuse-deterrent opioid analgesic formulation.

Field of Use
The Field of Use apply to the healthcare industry.

IPSCIO Record ID: 260417

License Grant
This License agreement is pursuant to a certain Collaboration Agreement between the parties.

Licensor grants the following licenses under Licensors Technology and Licensors Patent Rights and under Licensors ownership interest in Joint Technology and Joint Patent Rights

For Development, an exclusive license in the U.S. Territory, beginning immediately upon approval by the FDA of the NDA for each Product, to conduct Product Development with respect to such Product, and, in the ROW, beginning immediately following the initiation of Phase II clinical trials for each Product by Licensor in the U.S. Territory, to conduct Product Development with respect to such Product, in the Territory, to conduct Development on Remoxy, and in the Territory, to conduct Development on Products, exercisable only in the event that Licensor suspends, closes or otherwise ceases to operate a majority of its business relating to this Agreement and the Collaboration Agreement, or in any case commenced by or against Licensor under the Bankruptcy Code, upon entry of an appropriate order or findings by the court presiding over such case, Licensor is in material breach of this Agreement or the Collaboration Agreement and such breach is not cured within sixty (60) days of the occurrence of the breach or Licensor rejects this Agreement or the Collaboration Agreement.

For Commercialization, an exclusive license in the Territory to Market, use, offer for sale, sell and import Products.

This agreement includes non-exclusive grants from Licensee to Licensor.

License Property
The Product means any dosage form of Remoxy,  an abuse-resistant opioid painkiller, and any other product in the Field that incorporates the SABER Technology and is covered by the rights licensed to Licensor under the DLA, the Development and License Agreement, dated as of December 19, 2002, and that is Developed or Marketed pursuant to the Collaboration Agreement.

REMOXY means a drug product in the Field that contains oxycodone as its opioid API and that is formulated using the SABER Technology.

SABER Technology means the pharmaceutical formulation technology and methods of use that are covered by the rights granted to Licensor pursuant to the DLA.

Field of Use
The Field means pharmaceutical formulations for use in humans that contain no more than one opioid API formulated using the SABER Technology, in accordance with the DLA.

IPSCIO Record ID: 5599

License Grant
The agreement granted a non-exclusive license and sublicense to use the oral formulations of these two product candidates and  granted a non-exclusive license to use its controlled release technologies.
License Property
Bicifadine is a serotonin-norepinephrine reuptake inhibitor (SNRI).  It has been developed as an analgesic and is currently under development for the treatment of various pain conditions. Phase III trials were completed in 2006 for treating chronic low back pain, and the drug is currently being tested to assess its efficacy in treating pain associated with osteoarthritis, acute post-surgical pain, neuropathic pain and pain associated with dental surgery. Its usefulness in surgical or dental pain is dubious, however, as most monoamine uptake-inhibiting antidepressants have little effect in treating acute pain–they are far more effective in cases of chronic, neuropathic pain.
Field of Use
The newly formed Licensee develops controlled release formulations of bicifadine for the treatment of pain and ocinaplon for the treatment of anxiety disorders and epilepsy.

IPSCIO Record ID: 2633

License Grant
The companies announced pursuant to a strategic alliance, the initiation of a Phase I clinical trial program of second abuse resistant drug candidate, called PTI-202.
License Property
In connection with the acceptance by the FDA of the investigational new drug application, or IND, for PTI-202, the company made a milestone payment. In connection with this milestone, we made a milestone payment of an undisclosed amount to a third party, pursuant to our agreement with that third party. The company is obligated to reimburse us for costs, including milestones, we incur under our agreement with the third party, pursuant to our collaboration with the company.  We could also receive up to an additional $dollars in additional milestone payments in the course of clinical development of Remoxy and other abuse-resistant opioid pain killers under the strategic alliance. In addition, subject to certain limitations, the company is obligated to fund development expenses incurred by us related to Remoxy and other abuse-resistant opioid pain killers pursuant to the collaboration agreement. The company is obligated to fund the commercialization expenses of, and has the exclusive right to market and sell, drugs developed in connection with the strategic alliance.

IPSCIO Record ID: 4395

License Grant
The Licensor entered into a strategic alliance Agreement with the Licensor with respect to the development of oxymorphone ER, an extended release formulation of oxymorphone based on our TIMERx technology.
License Property
Oxymorphone ER is a narcotic analgesic that the Licensor is  developing with the Licensee using our proprietary TIMERx technology for twice-a-day dosing in patients with moderate to severe pain requiring continuous, around-the-clock opioid therapy for an extended period of time.
Field of Use
Oxymorphone ER, if approved, would compete in the market for long acting, strong opioids with products such as Purdue Pharma’s OxyContin and Johnson and Johnson’s Duragesic patch.

The Licensee is an integrated specialty pharmaceutical company with a market leadership position in pain management.

IPSCIO Record ID: 3297

License Grant
This Agreement settles the parties patent infringement litigation concerning Licensor's AVERSION® oxycodone product, previously marketed by Pfizer Inc. under its brand name Oxecta® (oxycodone HCI tablets).

In the suit, Licensor alleges that a generic AVERSION® oxycodone product for which Licensee is seeking approval to market in the U.S. pursuant to an Abbreviated New Drug Application filing with the U.S. Food and Drug Administration infringes a U.S. patent owned by Licensor .

Under the terms of the Settlement Agreement, Licensor will grant Licensee a non-exclusive, royalty-bearing license to the Licensor Patent and other current and future Orange Book listable patents to market, manufacture and sell a generic version of AVERSION® oxycodone in the United States. Licensee's license becomes effective 180 days following the first sale of a generic AVERSION® oxycodone

product in the United States by an entity that is entitled to the 180 day first-filer exclusivity provided in the Drug Price Competition.

The Settlement Agreement will remain in effect until the expiration of the term of the license granted by tbe Licensor to the Licensee.

License Property
AVERSION® oxycodone is a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain where the use of an opioid analgesic is appropriate.

IPSCIO Record ID: 253953

License Grant
The Parties have entered into a Settlement Agreement.  As a result of and pursuant to the Settlement Agreement,  the Licensor grants a limited, non-exclusive,  non-transferable license of limited duration under the Patent to make, have made, use, offer to Sell and Sell, in the United States, up to an aggregate of 800,000 bottles, subject to the reductions set forth below, of the generic versions of 10 mg, 15mg, 20 mg, 30 mg, 40 mg, 60 mg and 80 mg dosage strengths of the Licensee Products, allocated among the dosage strengths.
License Property
The patent is relating to and protecting controlled-release oxycodone products, including the product OxyContin®, a controlled-release oxycodone product marketed and sold under NDA No. 20-553 OxyContin®.
Field of Use
Licensee is a specialty branded pharmaceutical company.  The product is for the management of pain with opioid analgesics.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.